论文部分内容阅读
目的探讨重组人促红细胞生成素(rhu-EPO)对新生儿缺氧缺血性脑病的治疗效果。方法将141例缺氧缺血性脑病患儿随机分为rhu-EPO治疗组(n=72)和对照组(n=69),治疗组于生后第5天给予rhu-EPO 500 IU/kg,每周3次,一个疗程4周,其它治疗措施同对照组。于胎龄40周时进行新生儿行为神经测定(NBNA),并随访后遗症的发生率。结果治疗组患儿在胎龄40周时的NBNA得分为38.10±1.91,明显高于对照组36.35±1.99(t=4.2330,P=0.000)。至2岁时后遗症的发生率明显降低。结论rhu-EPO对缺氧缺血性脑病患儿神经行为发育有促进作用,并能减少缺氧缺血性脑病后遗症的发生。
Objective To investigate the therapeutic effect of recombinant human erythropoietin (rhu-EPO) on neonatal hypoxic-ischemic encephalopathy. Methods 141 children with hypoxic ischemic encephalopathy were randomly divided into rhu-EPO treatment group (n = 72) and control group (n = 69). The treatment group received rhu-EPO 500 IU / kg , 3 times a week, a course of 4 weeks, other treatment with the control group. Neonatal behavioral nerve assay (NBNA) was performed at 40 weeks gestational age and the incidence of sequelae was followed up. Results The score of NBNA in the treated group was 38.10 ± 1.91 at 40 weeks gestational age, which was significantly higher than that of the control group 36.35 ± 1.99 (t = 4.2330, P = 0.000). By the age of 2, the incidence of sequelae decreased significantly. Conclusion rhu-EPO can promote neurobehavioral development in children with hypoxic-ischemic encephalopathy and reduce the occurrence of sequelae of hypoxic-ischemic encephalopathy.